Helicobacter pylori and early gastric cancer

M E Craanen, P Blok, W Dekker, G N J Tytgat

Abstract

The relation between *Helicobacter pylori*, intestinal metaplasia, and early gastric cancer was studied by examining gastrectomy specimens from 31 intestinal type and 22 diffuse type carcinomas. A total of 298 patients with antral gastritis were used as controls. Atrophic changes and intestinal metaplasia were significantly more common in intestinal type early gastric cancer compared with diffuse type early gastric cancer ($p < 0.05$ and $p < 0.001$, respectively). *H pylori* was found in 61.3% of intestinal type early gastric cancer and in 54.5% of diffuse type early gastric cancer (NS). The age adjusted prevalence of intestinal metaplasia in the patients with antral gastritis was higher in *H pylori* positive patients in all age groups studied. Comparing gastritis patients with patients with intestinal type early gastric cancer showed the age adjusted prevalence of intestinal metaplasia to be significantly higher in the patients with early gastric cancer in all age groups studied. In conclusion, *H pylori* is associated with both types of early gastric carcinoma. Intestinal metaplasia formation seems to be a multifactorial process in which *H pylori* may play a part. These findings suggest that gastric cancer may be included in the spectrum of *H pylori* associated diseases, although many questions about causality remain to be answered.

(Gut 1994; 35: 1372-1374)

Several follow up studies on gastritis suggest a slow and gradual progression of chronic active gastritis to chronic gastritis with variable degree of atrophy and intestinal metaplasia.¹⁻⁴ Chronic atrophic gastritis and intestinal metaplasia are widely recognised as being the most prevalent of all conditions associated with an increased gastric cancer risk.^{5,6} In view of these data and in recognition of the important role of *Helicobacter pylori* (*H pylori*) in the gastric inflammatory process, it is not surprising that its potential role in the development of premalignant and malignant changes in the stomach is a subject of interest. Several histological studies have reported on the association between *H pylori* and gastric carcinoma using mainly gastrectomy specimens from advanced cancers.⁷⁻⁹ We feel that studying the mucosal characteristics of stomachs harbouring early gastric carcinoma is more suitable for studying the association between *H pylori* and tumour histology. This is based on the assumption that the mucosa of such stomachs is more preserved than the mucosa of stomachs

harbouring advanced cancers. This study, therefore, reports the prevalence of *H pylori* in both types of gastric carcinoma using gastrectomy specimens from early cancers. The possible role of *H pylori* in the development of intestinal metaplasia is further explored by comparing age grouped data from patients with antral gastritis and both types of early gastric cancer.

Methods

For the purpose of this study, all gastrectomy specimens of early gastric carcinomas diagnosed in the period 1973 to 1990 were retrieved from the files of the pathology department (Public Health Laboratory Haarlem). The gastrectomy specimens were opened along the greater curvature and pinned out on to a cork mat. After fixation in 10% buffered formalin, multiple blocks were taken from the tumour, its surrounding mucosa, antrum, and body (proximal resection margin in most cases). A section was also taken from the lesser curvature. All samples were embedded in paraffin wax, cut at 5 μ and stained with haematoxylin and eosin for diagnosis. Early gastric cancer was defined as carcinoma confined to the mucosa or submucosa with or without lymph node metastasis according to the Japanese Gastrointestinal Endoscopy Society.¹⁰ A total of 53 cases was identified. The tumour site was noted and the tumour type according to Lauren¹¹ was reassessed independently by two of the authors (MC/PB). Discrepancies in findings, although rare, were discussed until agreement was reached. All tissue blocks of non-malignant antral mucosa were recut and stained by haematoxylin and eosin and Giemsa. The presence of *H pylori*, the type of gastritis, and the presence and extent of intestinal metaplasia were assessed according to the Sydney system.^{12,13} From our previously reported prospective endoscopic-biopsy study,¹⁴ subjects with a histological diagnosis of antral gastritis ($n = 298$) were used as controls. This group of patients was stratified according to age and the presence of intestinal metaplasia and *H pylori*

TABLE 1 Grades of *H pylori* density in early gastric carcinoma according to the Sydney classification

Density	I-EGC ($n = 31$) (%)	D-EGC ($n = 22$)
0	12 (38.7)	10 (45.5)
1	7 (22.6)	8 (36.4)
2	12 (38.7)	4 (18.1)
3	0 (0)	0 (0)

0: *H pylori* absent, 1; individual organisms or small groups covering less than one third of the mucosal surface, 2; between 1 and 3, 3; the presence of large groups of organisms on the surface and upper pits of more than two third of mucosal surface examined. I-EGC=intestinal type early gastric cancer, D-EGC=diffuse type early gastric cancer.

Department of
Gastroenterology and
Hepatology, Academic
Medical Centre,
Amsterdam, The
Netherlands
G N J Tytgat

Department of
Medical Oncology, The
Netherlands Cancer
Institute, Amsterdam,
The Netherlands
M E Craanen

Department of
Pathology, Public
Health Laboratory,
Haarlem, The
Netherlands
P Blok

Department of
Internal Medicine,
Kennemer Gasthuis,
Haarlem, The
Netherlands
W Dekker

Correspondence to:
Dr M E Craanen,
Department of Medical
Oncology, The Netherlands
Cancer Institute,
Plesmanlaan 121, 1066CX
Amsterdam, The
Netherlands.

Accepted for publication
31 January 1994

TABLE II Prevalence of *H pylori* according to age group and histological tumour type

Age (y)	Number	HP+ (%)	I-EGC: D-EGC	% I-EGC HP+ (n)	% D-EGC HP2 (n)
30-39	1	0 (0)	0:1	NA	NA
40-49	5	2 (40)	1:4	NA	50 (2)
50-59	16	11 (68.8)	5:11	100 (5)	54.5 (6)
60-69	13	8 (61.5)	10:3	60 (6)	66.6 (2)
70-79	10	6 (60)	8:2	50 (4)	100 (2)
≥80	8	4 (50)	7:1	57 (4)	0 (0)
Total	53	31 (58.5)	31:22	61.3 (19)	54.5 (12)

HP=*H pylori*, I-EGC=intestinal type early gastric carcinoma, D-EGC=diffuse type early gastric carcinoma, NA=not applicable.

were reassessed independently by two of the authors (MC/PB). Finally, age grouped data of patients with antral gastritis were compared with similar data of patients with both types of early gastric cancer for the prevalence of *H pylori* and intestinal metaplasia.

STATISTICS
The χ^2 test and the two tailed Student's *t* test were used to analyse the data, when appropriate.

Results

EARLY GASTRIC CANCER PATIENTS
Thirty seven early gastric cancers were found in the antrum, 13 in the body, and three in the cardia/fundic region. There were 31 intestinal type early gastric cancers (median age 69) and 22 diffuse type early gastric cancer (median age 58.5). Atrophic mucosal changes were present in 90.3% (28 of 31) of intestinal type early gastric cancer and in 63.6% (14 of 22) of diffuse type early gastric cancer ($p<0.05$). No significant difference in grade of atrophy was detected. Intestinal metaplasia was found in the mucosa surrounding intestinal type early gastric cancer and diffuse type early gastric cancer in 96.8% and 45.5% of the cases, respectively ($p<0.001$). Moderate to severe intestinal metaplasia was only found in cases of intestinal type early gastric cancer ($p<0.001$). *H pylori* was found in the non-malignant antral mucosa of 61.3% (19 of 31) of intestinal type and in 54.5% (12 of 22) of diffuse type early gastric cancer (NS). No significant difference in bacterial load was found between both types (Table 1). When stratified according to age group, no significant difference in prevalence of *H pylori* was found either between intestinal and diffuse type tumours (Table II).

TABLE III Prevalence of intestinal metaplasia per age group according to *H pylori* status in gastritis patients

Age (y)	Number	HP+ (n)	IM+ (%)	HP- (n)	IM+ (%)
20-29	16	10	10	6	0
30-39	26	23	23	3	0
40-49	45	34	20.6	11	9.1
50-59	61	57	31.8	4	25
60-69	60	49	36.7	11	18.2
70-79	56	43	51.2	13	23.1
≥80	34	12	58.3	22	22.7
Total	298	228	33.3*	70	17.4

* $p<0.02$, HP=*H pylori*, IM=intestinal metaplasia.

GASTRITIS PATIENTS
There were 298 patients with histological diagnosis of antral gastritis. A total of 1082 antral biopsy specimens were examined (mean (SEM) 3.6 (2.8) per patient). *H pylori* was found in 228 patients (76.5%). Intestinal metaplasia was found in 88 patients (29.5%). Its prevalence increased with age. The prevalence of intestinal metaplasia was higher in the *H pylori* positive group than in the *H pylori* negative group (33.3% *v* 17.4%, $p<0.02$). The extent of intestinal metaplasia in the last two groups was not significantly different. In each age group the prevalence of intestinal metaplasia was higher in the *H pylori* positive patients than in the *H pylori* negative patients, although these differences did not reach statistical significance (Table III).

COMPARISON BETWEEN GASTRITIS AND EARLY GASTRIC CANCER PATIENTS
Age adjusted comparison between patients with intestinal type early gastric cancer and gastritis patients showed the antral prevalence of intestinal metaplasia to be significantly higher in early gastric cancer patients (Table IV). No significant difference in prevalence of *H pylori* was found. Comparison between gastritis patients and patients with diffuse type early gastric cancer showed no significant difference in prevalence of *H pylori* and intestinal metaplasia.

Discussion
At present, conflicting data from various histological studies on the association between *H pylori* and both Lauren types of gastric carcinoma can be found in published reports. One retrospective histological study reported a strong association between *H pylori* infection and intestinal type but not diffuse type gastric carcinoma.⁷ Other investigators, however, did not find a significant difference in association between *H pylori* and both types of gastric carcinoma.^{8,9} The last three histological studies only focused on the mucosal background of advanced cancers. In our study, using only early gastric cancers, *H pylori* associated gastritis was the mucosal background lesion in most diffuse type early cancers as well. No significant difference in the prevalence of *H pylori* between both types of early gastric cancer was found. A confounding factor might be the gastric mucosa becoming increasingly inhospitable for *H pylori* in the process of progressive atrophy and intestinal metaplasia formation. The higher prevalence of atrophy and intestinal metaplasia in intestinal type early gastric cancer in our study may have led to the disappearance of the micro-organism resulting in a lower observed than expected prevalence of *H pylori* in cases of intestinal type early gastric cancer. Nevertheless, in view of the generally accepted pathogenesis of both types of gastric cancer,¹⁵⁻¹⁷ it might have been expected that there would be a strong association between *H pylori* and intestinal type tumours only. Our study

TABLE IV Age related comparison of the prevalence of *H pylori* and intestinal metaplasia in patients with antral gastritis (n=298) and early gastric carcinoma (n=53)

Age (y)	Gastritis HP+ (%)	IM+ (%)	I-EGC HP+ (%)	IM+ (%)	D-EGC HP+ (%)	IM+ (%)
20-29	62.5	6.25	NA	NA	NA	NA
30-39	88.4	11.5	NA	NA	NA	NA
40-49	75.6	17.8	NA	NA	50	25
50-59	93.4	31.1	100	100*	54.5	54.5
60-69	80.3	33.3	60	100†	66.6	66.6
70-79	76.8	44.6	50	100‡	100	50
≥80	35.3	35.3	57.1	100§	NA	NA

IM; gastritis v, intestinal type early gastric carcinoma, *p<0.01, †p<0.001, ‡p<0.05, §p<0.01. Abbreviations as in Table II.

clearly shows, however, a strong association between *H pylori* and diffuse type tumours as well. Our finding is in agreement with several serological studies reporting on the association between *H pylori* and gastric carcinoma.^{18 19} Sipponen *et al* postulate that the morphogenesis of gastric cancer may depend on the stage of the *H pylori* related gastritis. Chronic inflammation may particularly promote the morphogenesis of diffuse type carcinoma, whereas the atrophic and metaplastic changes promote and favour the morphogenesis of intestinal type carcinoma.²⁰ Recent data on HLA-DR antigen expression in gastritis and gastric carcinoma, however, do not support Sipponen's view, but rather suggest that both types of gastric cancer constitute two distinct subtypes, only the intestinal type arising from the HLA-DR positive epithelial of chronic gastritis.^{21 22}

The risk of gastric carcinoma attributable to *H pylori* has been estimated at roughly 60%.^{18 19} To establish a better understanding of how *H pylori* might participate in gastric cancer development, it is important to elucidate its role in the preneoplastic process leading to gastric carcinoma. Intestinal metaplasia, generally considered a marker of premalignant change leading to gastric cancer of the intestinal type, was found more often in gastritis patients in all age groups studied in case they were *H pylori* positive. Other reports show similar results.^{23 24} This suggests that *H pylori* is indeed a factor in intestinal metaplasia development, possibly by inducing a hyperproliferative state in the inflamed mucosa.^{25 26} Moreover, the age adjusted prevalence of intestinal metaplasia was higher in patients with intestinal type early gastric cancer than in patients with gastritis. As *H pylori* induced gastritis was the background lesion in most of the intestinal type cancers, it is suggested that gastritis and intestinal metaplasia progress more rapidly in patients prone to intestinal type tumours than in patients with gastritis. Sipponen *et al* reported similar data.^{27 28} This rapid progression probably results from a multifactorial process, in which environmental, dietary, and genetic factors all play a part.

In conclusion, it is suggested that *H pylori* induced gastritis may evolve into intestinal metaplasia. It seems that *H pylori* relates to both types of gastric cancer, in what is in all probability a dynamic multifactorial process. It is therefore mandatory to devise a programme to prevent or to cure the infection and then to find out if this intervention reduces the risk of

one or both types of gastric cancer or changes the natural history of *H pylori* induced mucosal injury, or both.

1 Ihmaki T, Kekki M, Sipponen P, Siurala M. The sequelae and course of chronic gastritis during a 30-34 year biopptic follow-up study. *Scand J Gastroenterol* 1985; 20: 485-91.

2 Villako K, Kekki M, Tamm R, Tammur R, Savisaar E, Viirsalu V, *et al*. Epidemiology and dynamics of gastritis in a representative sample of Estonian urban population. *Scand J Gastroenterol* 1982; 17: 601-7.

3 Villako K, Kekki M, Maaros H-I, Spönnen P, Uibo R, Tammur R, *et al*. Chronic gastritis: progression of inflammation and atrophy in a six year endoscopic follow-up of a random sample of 142 Estonian urban subjects. *Scand J Gastroenterol* 1991; 26 (suppl 186): 135-41.

4 Kekki M, Siurala M, Varis K, Sipponen P, Sistonen P, Nevalinna RH. Classification principles and genetics of chronic gastritis. *Scand J Gastroenterol* 1987; 22: (suppl 141): 1-28.

5 Correa P. Precursors of gastric and esophageal cancer. *Cancer* 1982; 50: 2554-65.

6 Sipponen P, Kekki M, Haapakoski J, Ihmaki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross sectional data. *Int J Cancer* 1985; 35: 173-7.

7 Parsonnet J, Vandersteen DP, Goates J, Sibley RK, Pritikin J, Chang Y. *Helicobacter pylori* in intestinal- and diffuse-type gastric adenocarcinomas. *J Natl Cancer Inst* 1991; 83: 640-3.

8 Loffeld RJLF, Willems I, Flendrig JA, Arends JW. *Helicobacter pylori* and gastric carcinoma. *Histopathology* 1990; 17: 537-41.

9 Wee A, Kang JY, Teh M. *Helicobacter pylori* and gastric cancer: correlation with gastritis, intestinal metaplasia, and tumour histology. *Gut* 1992; 33: 1029-32.

10 Murakami T. Pathomorphological diagnosis. Definition and gross classification of early gastric cancer. In: Murakami T, ed. *Early gastric cancer. Gann monograph on cancer research*. Tokyo: University of Tokyo Press, 1971; 11: 53-5.

11 Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. *Acta Pathol Microbiol Scand* 1965; 64: 31-49.

12 Misiewicz JJ. The Sydney system: a new classification of gastritis. Introduction. *J Gastroenterol Hepatol* 1991; 6: 207-8.

13 Price AB. The Sydney system: histological division. *J Gastroenterol Hepatol* 1991; 6: 209-22.

14 Craanen ME, Dekker W, Blok P, Ferwerda J, Tytgat GNJ. Intestinal metaplasia and *Helicobacter pylori*: an endoscopic-biopptic study of the gastric antrum. *Gut* 1992; 33: 16-20.

15 Correa P. A human model of gastric carcinogenesis. *Cancer Res* 1988; 48: 1319-26.

16 Taki K, Kuwabara N. Studies on histogenesis of the gastric carcinoma using minute cancers. *Pathol Res Pract* 1981; 72: 176-90.

17 Hirota T, Itabashi M, Suzuki K, Yoshida S. Clinicopathologic study of minute and small early gastric cancer. *Pathol Annu* 1980; 15: 1-19.

18 Nomura A, Stemmermann GN, Chyou P-H, Kato I, Perez-Perez GI, Blaser MJ. *Helicobacter pylori* infection and gastric carcinoma among Japanese Americans in Hawaii. *N Engl J Med* 1991; 325: 1132-6.

19 Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, *et al*. *Helicobacter pylori* infection and the risk of gastric carcinoma. *N Engl J Med* 1991; 325: 1127-31.

20 Sipponen P, Kosunen TU, Valle J, Riihela M, Seppala K. *Helicobacter pylori* infection and chronic gastritis in gastric cancer. *J Clin Pathol* 1992; 45: 319-23.

21 Wee A, Teh M, Kang JY. Association of *Helicobacter pylori* with HLA-DR antigen expression in gastritis. *J Clin Pathol* 1992; 45: 30-3.

22 Teh M, Lee Y-S. HLA-DR antigen expression in intestinal-type and diffuse type gastric carcinoma. *Cancer* 1992; 69: 1104-7.

23 Rugge M, Mario di F, Cassaro M, Baffa R, Farinati F, Rublo J, *et al*. Pathology of the gastric antrum and body associated with *Helicobacter pylori* infection in non-ulcerous patients: is the bacterium a promoter of intestinal metaplasia? *Histopathology* 1993; 22: 9-15.

24 Guarner J, Mohar A, Parsonnet J, Halperin D. The association of *Helicobacter pylori* with gastric cancer and preneoplastic lesions in Chiapas, Mexico. *Cancer* 1993; 71: 297-301.

25 Scott N, Lansdown M, Diamant R, Rathbone B, Murday V, Wyatt JL, *et al*. *Helicobacter gastritis* and intestinal metaplasia in a gastric cancer family. [Letter]. *Lancet* 1990; 335: 728.

26 Correa P, Ruiz B. *Campylobacter pylori* and gastric cancer. In: Rathbone BJ, Heatley RV, eds. *Campylobacter pylori and gastroduodenal disease*. Oxford: Blackwell Scientific, 1989: 139-45.

27 Sipponen P, Kekki M, Siurala M. Atrophic gastritis and intestinal metaplasia in gastric carcinoma. Comparison with a representative population sample. *Cancer* 1983; 52: 1062-8.

28 Sipponen P, Kekki M, Siurala M. Age-related trends of gastritis and intestinal metaplasia in gastric carcinoma patients and in controls representing the population at large. *Br J Cancer* 1984; 49: 521-30.